Cite
Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
MLA
Hill, Colin S., et al. “Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.” Practical Radiation Oncology, vol. 12, no. 6, Nov. 2022, pp. 511–23. EBSCOhost, https://doi.org/10.1016/j.prro.2022.02.009.
APA
Hill, C. S., Rosati, L., Wang, H., Tsai, H.-L., He, J., Hacker-Prietz, A., Laheru, D. A., Zheng, L., Sehgal, S., Bernard, V., Le, D. T., Pawlik, T. M., Weiss, M. J., Narang, A. K., & Herman, J. M. (2022). Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation Oncology, 12(6), 511–523. https://doi.org/10.1016/j.prro.2022.02.009
Chicago
Hill, Colin S, Lauren Rosati, Hao Wang, Hua-Ling Tsai, Jin He, Amy Hacker-Prietz, Daniel A Laheru, et al. 2022. “Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.” Practical Radiation Oncology 12 (6): 511–23. doi:10.1016/j.prro.2022.02.009.